Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
A 5-phosphodiesterase inhibitor with uses similar to sildenafil, used in the treatment of pulmonary hypertension (including in children: Takatsuki 2012), erectile dysfunction in men, Raynaud's syndrome and in other treatments due to its vasodilatory effect on smooth muscle.
Since the last update, we have not found published data on its excretion in breast milk.
Its high percentage of protein binding makes it unlikely that it will be transferred to milk in significant amounts, as in fact has been seen in another drug from the same therapeutic group, sildenafil.
Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity.